TY - JOUR
T1 - Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn
AU - Fendrick, A. Mark
AU - Shaw, Michael
AU - Schachtel, Bernard
AU - Allgood, Lisa
AU - Allgood, Greg
AU - Grender, Julie
AU - Peura, David
N1 - Funding Information:
Supported by Procter & Gamble Health Sciences Institute.
PY - 2004/1
Y1 - 2004/1
N2 - Background & Aims: The Food and Drug Administration approval and subsequent launch of over-the-counter (OTC) omeprazole raises the question whether consumers would use OTC omeprazole appropriately in a "real world" setting. Methods: A 3-month observational study was conducted in an OTC setting to determine whether consumers could (1) correctly self-select to use omeprazole for frequent heartburn, (2) comply with a product label that calls for 14 consecutive days of once-daily dosing, and (3) use more than 14 doses of medication only under the advice of a physician. Consumers were interviewed at 5 shopping malls in geographically distinct areas of the United States and asked whether they had heartburn. Of the 1999 self-reported heartburn sufferers, 866 determined the product was appropriate for their condition and purchased the product; of these, 758 (88%) returned diaries documenting product usage and physician contact. Results: OTC consumers accurately self-selected; more than 90% of participants had heartburn 2 or more days/week. Analysis of diary data showed a high degree of compliance to label use directions; only 3% of subjects took more than 14 doses without consulting a physician. After 3 months, 43% of subjects did not have recurrence of heartburn. Overall, 75% of subjects had contact with a physician about heartburn before, during, or soon after the study (26% contacted a physician during the 3-month study). Of the 758 subjects, only 1 subject took more than 14 tablets without consulting a physician and had recurrence of heartburn. Conclusions: Actual use data support that consumers accurately self-select if an OTC proton pump inhibitor is appropriate for use, comply with a 14-day regimen in the OTC setting, and appropriately seek physician involvement for longer-term management of frequent heartburn.
AB - Background & Aims: The Food and Drug Administration approval and subsequent launch of over-the-counter (OTC) omeprazole raises the question whether consumers would use OTC omeprazole appropriately in a "real world" setting. Methods: A 3-month observational study was conducted in an OTC setting to determine whether consumers could (1) correctly self-select to use omeprazole for frequent heartburn, (2) comply with a product label that calls for 14 consecutive days of once-daily dosing, and (3) use more than 14 doses of medication only under the advice of a physician. Consumers were interviewed at 5 shopping malls in geographically distinct areas of the United States and asked whether they had heartburn. Of the 1999 self-reported heartburn sufferers, 866 determined the product was appropriate for their condition and purchased the product; of these, 758 (88%) returned diaries documenting product usage and physician contact. Results: OTC consumers accurately self-selected; more than 90% of participants had heartburn 2 or more days/week. Analysis of diary data showed a high degree of compliance to label use directions; only 3% of subjects took more than 14 doses without consulting a physician. After 3 months, 43% of subjects did not have recurrence of heartburn. Overall, 75% of subjects had contact with a physician about heartburn before, during, or soon after the study (26% contacted a physician during the 3-month study). Of the 758 subjects, only 1 subject took more than 14 tablets without consulting a physician and had recurrence of heartburn. Conclusions: Actual use data support that consumers accurately self-select if an OTC proton pump inhibitor is appropriate for use, comply with a 14-day regimen in the OTC setting, and appropriately seek physician involvement for longer-term management of frequent heartburn.
UR - http://www.scopus.com/inward/record.url?scp=0842329666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0842329666&partnerID=8YFLogxK
U2 - 10.1016/S1542-3565(03)00287-8
DO - 10.1016/S1542-3565(03)00287-8
M3 - Article
C2 - 15017628
AN - SCOPUS:0842329666
SN - 1542-3565
VL - 2
SP - 17
EP - 21
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 1
ER -